• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

1041469-97-9 (RKS262)

1

Identification

RKS262 RKS262
Name RKS262
Formula C15H14BrClN2O4S
MW 433.7
CAS No. 1041469-97-9
EINECS
Smiles C1(=O)OC2=CC=C(Br)C=C2C(Cl)=C1/C=N/N1CCS(=O)(=O)CC1C
Synonyms RKS262; RKS 262; RKS-262
InChI InChI=1S/C15H14BrClN2O4S/c1-9-8-24(21,22)5-4-19(9)18-7-12-14(17)11-6-10(16)2-3-13(11)23-15(12)20/h2-3,6-7,9H,4-5,8H2,1H3/b18-7+
2

Introduction

RKS262 is a CDK1/4  inhibitor.

Background Information

RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cy ......by BOC Sciences
RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several non-small cell lung cancer cell lines and few cell lines from other tissues were relatively resistant (GI(50) > 1 µM) to RKS262 treatment. ......by MedKoo Biosciences, Inc.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB100127285

Storage condition

Solubility

5

Mechanism and Indication

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
7

Safety Data of RKS262

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
BOC Sciences
MedKoo Biosciences, Inc. USA
Shanghai Haoyuan Chemexpress Co., Ltd. China
10

Related Products

Other Forms of 1041469-97-9

Name CAS No Formula MW

Recommended Compounds in CDK

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

RKS262

Tags: buy 1041469-97-9 IC50 | 1041469-97-9 price | 1041469-97-9 cost | 1041469-97-9 solubility | 1041469-97-9 purchase | 1041469-97-9 manufacturer | 1041469-97-9 research buy | 1041469-97-9 order | 1041469-97-9 MSDS | 1041469-97-9 chemical structure | 1041469-97-9 Storage condition | 1041469-97-9 molecular weight | 1041469-97-9 mw | 1041469-97-9 datasheet | 1041469-97-9 supplier | 1041469-97-9 cell line | 1041469-97-9 NMR | 1041469-97-9 MS | 1041469-97-9 IR | 1041469-97-9 solubility | 1041469-97-9 Safe information | 1041469-97-9 Qc and Spectral Information | 1041469-97-9 Clinical Information | 1041469-97-9 Clinical Trial | 1041469-97-9 Route of Synthesis | 1041469-97-9 storage condition | 1041469-97-9 diseases and conditions | 1041469-97-9 flash point | 1041469-97-9 boiling point | 1041469-97-9 melting point | 1041469-97-9 storage condition | 1041469-97-9 brand